Levosimendan for Cardiac Patients Undergoing Major Abdominal Cancer Surgeries

• Status: Completed
• Trial end date: 2018-04-23
• Target enrollment: 0
• Participant gender: All

Summary

The objective of this pilot study is to evaluate the efficacy and safety of preoperative administration of levosimendan in patients with chronic heart failure scheduled for major abdominal cancer surgery assuming the reduction of both perioperative morbidity and mortality.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: National Cancer Institute, Egypt
• Treatments: Simendan

Criteria

Inclusion Criteria:

• Patients suffering from CHF with left ventricular ejection fraction < 35%, scheduled for major abdominal cancer surgery were eligible.

• Aged 18 to 75 years.

Exclusion criteria were :

• restrictive or obstructive cardiomyopathy.

• severe cardiac valvular disease.

• history of atrial fibrillation, ventricular tachycardia or fibrillation.

• resting systolic arterial pressure <80 mmHg.

• second or third degree atrioventricular block.

• Child-Pugh class C liver cirrhosis.

• severe renal failure (defined as creatinine clearance < 30 ml/min).

• Immediate postoperative complications such as surgical re-exploration for bleeding or suspected leak.